NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Categories: Bloomberg

11/19/2018

Bloomberg uncritically touts ‘greater effectiveness’ of cell-based flu vaccine

5/22/2018

A study that may help reduce overtreatment of breast cancer gets solid write-up by Bloomberg

2/7/2018

Disease-mongering dogs Bloomberg’s story on prostate cancer drugs

2/6/2018

Bloomberg highlights modest weight loss benefit from standing desks study. Missing: a focus on better alternatives

8/15/2017

Strong recap on cancer blood test should have challenged survival claims

6/7/2017

Bloomberg offers up balanced recap of new breast cancer therapy

1 5/22/2017

Bloomberg story provides clear-eyed view of trendy neurofeedback brain-training clinics

3/20/2017

Bloomberg paints rosy picture of virtual reality for PTSD, glossing over the hard evidence

11/21/2016

Bloomberg’s conflicted sources ‘love’ new cholesterol drugs — readers need to know about financial relationships with pharma

8/30/2016

Bloomberg’s story on virtual reality for pain control was a little too rosy